CN1872250B - Composition of medication for treating headache - Google Patents
Composition of medication for treating headache Download PDFInfo
- Publication number
- CN1872250B CN1872250B CN2005100136267A CN200510013626A CN1872250B CN 1872250 B CN1872250 B CN 1872250B CN 2005100136267 A CN2005100136267 A CN 2005100136267A CN 200510013626 A CN200510013626 A CN 200510013626A CN 1872250 B CN1872250 B CN 1872250B
- Authority
- CN
- China
- Prior art keywords
- filtrate
- volatile oil
- adjuvant
- medicine
- standby
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 105
- 206010019233 Headaches Diseases 0.000 title claims abstract description 20
- 231100000869 headache Toxicity 0.000 title claims abstract description 20
- 239000000203 mixture Substances 0.000 title claims description 53
- 229940079593 drug Drugs 0.000 title description 34
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 39
- 239000000706 filtrate Substances 0.000 claims description 102
- 239000006187 pill Substances 0.000 claims description 99
- 239000000843 powder Substances 0.000 claims description 86
- 239000002671 adjuvant Substances 0.000 claims description 82
- 239000000341 volatile oil Substances 0.000 claims description 68
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 50
- 238000003756 stirring Methods 0.000 claims description 50
- 238000002360 preparation method Methods 0.000 claims description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 39
- 239000002994 raw material Substances 0.000 claims description 37
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 34
- 229920002472 Starch Polymers 0.000 claims description 33
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 33
- 239000008107 starch Substances 0.000 claims description 33
- 235000019698 starch Nutrition 0.000 claims description 33
- 235000010447 xylitol Nutrition 0.000 claims description 33
- 239000000811 xylitol Substances 0.000 claims description 33
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical group OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 33
- 229960002675 xylitol Drugs 0.000 claims description 33
- 239000007788 liquid Substances 0.000 claims description 19
- 238000002156 mixing Methods 0.000 claims description 19
- 238000001035 drying Methods 0.000 claims description 18
- 238000000605 extraction Methods 0.000 claims description 18
- 238000001914 filtration Methods 0.000 claims description 17
- 238000002844 melting Methods 0.000 claims description 17
- 230000008018 melting Effects 0.000 claims description 17
- 238000001256 steam distillation Methods 0.000 claims description 17
- 239000002826 coolant Substances 0.000 claims description 16
- 238000010438 heat treatment Methods 0.000 claims description 16
- 238000009413 insulation Methods 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 15
- 238000012856 packing Methods 0.000 claims description 14
- 229920002545 silicone oil Polymers 0.000 claims description 13
- 239000004615 ingredient Substances 0.000 claims description 11
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 244000001632 Acorus gramineus Species 0.000 abstract 1
- 235000013073 Acorus gramineus Nutrition 0.000 abstract 1
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 239000000758 substrate Substances 0.000 description 43
- 238000000034 method Methods 0.000 description 19
- 238000012360 testing method Methods 0.000 description 17
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 239000008101 lactose Substances 0.000 description 14
- 241000196324 Embryophyta Species 0.000 description 12
- 235000010489 acacia gum Nutrition 0.000 description 12
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 11
- 239000002202 Polyethylene glycol Substances 0.000 description 10
- 229920001223 polyethylene glycol Polymers 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 8
- 239000000284 extract Substances 0.000 description 7
- -1 hydroxypropyl Chemical group 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 239000000945 filler Substances 0.000 description 5
- 229940057995 liquid paraffin Drugs 0.000 description 5
- 229940032147 starch Drugs 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- 241001597008 Nomeidae Species 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 239000006225 natural substrate Substances 0.000 description 4
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 229920002101 Chitin Polymers 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 229920001277 pectin Polymers 0.000 description 3
- 239000001814 pectin Substances 0.000 description 3
- 235000010987 pectin Nutrition 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 230000035943 smell Effects 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000001407 Vascular Headaches Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241000209020 Cornus Species 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241001411320 Eriogonum inflatum Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 244000286663 Ficus elastica Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 244000275012 Sesbania cannabina Species 0.000 description 1
- 238000003723 Smelting Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- 235000004298 Tamarindus indica Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 229940125713 antianxiety drug Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000003578 releasing effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007560 sedimentation technique Methods 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 229960001947 tripalmitin Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000009284 zhennaoning Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
A Chinese medicine for treating headache is prepared from borneol, grass-leaved sweetflag rhizome, Chuan-xiong rhizome, dahurian angelica root and proper auxiliary.
Description
Technical field
The present invention relates to field of medicaments, particularly relating to Chinese medicine is the pharmaceutical preparation of the raw material treatment headache of making.
Background technology
Headache is a kind of common symptom in the daily life, and almost everyone all has the headache generation in life.The reason that causes headache is diversified.At present, the medicine of treatment headache both at home and abroad is a lot of at present, and the smelting of all can only suiting the medicine to the illness is treated, and pain relieving is main, and only a few adopts operative treatment, but effect is all undesirable, it is cured the symptoms, not the disease, and patient headache is outbreak repeatedly, and takes pain relieving class medicine for a long time and can produce drug resistance and addiction, so such medicine is difficult for taking for a long time, can not fundamentally solve the puzzlement of headache.In addition, also use antianxiety drug, resist melancholy agent, sympathetic inhibitor, calcium channel blocker, antiepileptic etc. clinically according to the different causes of disease, these side effects of pharmaceutical drugs are bigger, take for a long time curative effect is reduced gradually, so that patient's dosage of having to increase gradually, the result takes medicine many more, and it is but serious all the more to have a headache.Chinese patent medicine has ZHENGTIAN WAN, and it is the Chinese medicine and western medicine side of closing, and its mechanism is blood circulation promoting and blood stasis dispelling, and is furnished with the Western medicine analgesic, and uncertain therapeutic efficacy is cut, and is difficult to reach the purpose of radical cure.Patent Office of the People's Republic of China discloses a kind of treatment vascular headache new drug ZHENNAONING JIAONANG with CN1076620A, it is made up of Chinese medicine Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae, Medulla sus domestica, Rhizoma Gastrodiae, Herba Asari, Radix Puerariae, Pulvis Cornus Bubali Concentratus etc., its objective is in order to treat because of arteriosclerosis, hypertension and the caused nervous vascular Headache of some symptoms, its weak point is that therapeutic domain is narrow, and raw materials used medicine is numerous.
The synthetic chemical substance that modern medicine is commonly used has spreaded all over each corner of human lives, chemical synthetic drug becomes the main flow of medicine, yet, along with multiple difficult serious symptom, the appearance of miscellaneous diseases, western medical treatment presents imperfection, the human lives and the healthy reality and the up-to-date successes achieved in research have all proposed query to this situation, particularly along with the continuous appearance of chemical drugs toxic and side effects, the change of spectrum of disease and conversion of medical, make modern medicine be subjected to unprecedented challenge, and people also place hope in the application and development of traditional medicine on gradually.Advocate back to nature, pay attention to plant amedica use, hanker after traditional remedies, the trend of advocating natural drug forms, making full use of natural materials becomes human best selection gradually.
At present, in the world, natural drug all has certain market, along with people increasing and the aging of population to the health requirements level of understanding, sub-health stateization, people thirst for back to nature more, the problem of utilize the high Drug therapy of pure natural degree, preventing some chemical synthetic drugs cann't be solved, so the background that exceeds its original traditional national culture has been expanded in the application of natural plant.From natural drug, seek the little and inexpensive medicine of side effect and become the target that countries in the world pharmaceutical manufacturer is chased.The European Community has carried out unified legislation to medical herbs, state medical herbs status such as Canada and Australia have legalized, U.S. government has also drafted the plant amedica management method, the compound recipe mix preparation that begins to accept natural drug is as curative, and these provide good international environment for Chinese medicine enters international medical market as curative.On the other hand, along with the quickening of global economic integration progress, particularly China becomes a full member of WTO, and Chinese Medicine market incorporates the breadth and depth of international medical big market and will further aggravate.Face the enormous impact of Asian countries's traditional medicine product such as the keen competition of powerful transnational medical group and Japan, Korea S, India, Thailand and European countries' plant amedica such as Germany, France, numerous products that China's Chinese medicine produces are owing to still can not meet the standard of international medical market and requirement and being kept outside of the door.
Expansion and human back to nature requirement along with the market global range, use the low medicine of toxic and side effects, especially pure natural medical more and more becomes people's first-selection, dropping pill formulation be a kind of have efficient, quick-acting new medicine preparations, it has overcome the shortcoming and deficiency of Chinese medicine preparation in the past, but present dropping pill formulation generally faces following problem: 1, drop pill adjuvant pure natural degree is not high: at present, drop pill substrate adjuvant mostly is synthetic, natural degree is lower, the searching of new alternative substrate adjuvant, the searching of the alternative substrate adjuvant that particularly natural degree is high and preparation technology thereof determine, it is again very difficult thing, because the required preparation condition of at present common possible natural substrates adjuvant succedaneum is very harsh, it all is to influence the key that drop pill prepares molding that adjuvant temperature and drop pill thereof drip the system condition.The too high then viscosity of adjuvant melt temperature is low, and poor plasticity is though the adjuvant melt temperature is crossed lowplastcity by force, but drop pill has shortcomings such as easily sticking ball, distortion, therefore, seek pure natural degree height, and the adjuvant that is suitable for substituting existing drop pill substrate is a very job of hardships.2, the drop pill outlet encounters problems: along with expanding economy, more and more internationalize in market, China is also just making great efforts to adapt to this trend, present Chinese medicine dripping pills preparation as health food, successful export to many countries, but also face many problems at present, because different countries is different to the approval of the selected adjuvant of Chinese medicine dropping pill formulation, especially industrial flourishing Europe, more strict to food adjuvant and medical auxiliary materials, and as the selected chemosynthesis adjuvant (as Polyethylene Glycol) of the dropping pill formulation of health food outlet not in the catalogue of some national food additive, it is very unfavorable that this moves towards the international market to the Chinese medicine dropping pill formulation, becomes the stumbling-block that Chinese medicine enters the international market, therefore, seek the new of one or more, can be particularly important, also very urgent for the substrate adjuvant that the international market is accepted.3, the shortcoming of mouthfeel and onset speed: the mouthfeel of Chinese medicine and preparation thereof is relatively poor to be the big characteristics of one, people when taking some drugs to the frightened of disagreeable taste that medicine had even be better than fear far away to disease, What is more, some patients are because can not overcome the poor taste of Chinese medicine or its preparation or abnormal smells from the patient and abandon the treatment of Chinese medicine, though can improve mouthfeel as medicine being made capsule or sugar coated tablet, reducing stimulates, but disintegration rate prolongs, be unfavorable for the rapid onset of medicine, to some disease, particularly need the disease of the rapid onset of medicine inapplicable.4, the preparation process difficulty of drop pill suitability for industrialized production: in the replacement process of dropping pill formulation adjuvant, determining of the preparation process of its suitability for industrialized production is very difficult something, as the ratio of the melt temperature of substrate adjuvant, the proportioning of dripping system temperature, adjuvant and medicine, dropper bore, condensing agent etc. all are the factors that influence drop pill, therefore, the replacement of substrate and to be suitable for suitability for industrialized production be a job consuming time, as to expend substantial contribution.
In order to change drop pill substrate adjuvant for a long time based on the situation of chemosynthesis adjuvant, it is low to solve the pure natural degree that present drop pill substrate faced, and can not satisfy more and more that people require back to nature, take low toxicity, the problem of the pure natural medical that has no side effect; Also can solve some problems that Chinese medicine preparation, particularly dropping pill formulation are run in exit procedure, strengthen the competitiveness of international market; The present invention has invented the pure Chinese medicine dripping pills preparation that a kind of toxic and side effects is low, evident in efficacy, moderate, adapt to industrialized great production by a large amount of tests and the research of preparation process.
Summary of the invention
The purpose of this invention is to provide a kind of pharmaceutical composition of having a headache with the treatment of new type natural substrate adjuvant preparation.
Another object of the present invention provides a kind of preparation method for the treatment of the hedex compositions.
The selected substrate adjuvant of the present invention is resulting by a large amount of tests, it is little to have molecular weight, soluble in water, and molten diffusing speed is faster, pure natural degree height, toxic and side effects is low, and can reduce the medicine irritation abnormal smells from the patient, has the oral cavity of improvement acid-base value during the buccal of oral cavity, improve the characteristics of oral cavity smell, the used substrate adjuvant of the present invention is the agent of food sedan-chair flavor, takes that mouthfeel is good, the acceptant characteristics of patient, is the direction of following substrate adjuvant development.
The consumption of drug component of the present invention and the selection of adjuvant thereof also grope to sum up to draw through the inventor in a large number, this medicine is formed and is comprised: Borneolum Syntheticum 0.5～3 weight portion, Rhizoma Acori Graminei 15～40 weight portions, Rhizoma Chuanxiong 15～40 weight portions, the Radix Angelicae Dahuricae 15～40 weight portions, appropriate amount of auxiliary materials, wherein adjuvant comprises filler and plasticity substrate, said filler is selected from the natural adjuvant of following one or more plant origins: erythritol, sorbitol, fructose, D-ribonic acid-gamma lactone, arabitol, trehalose, D-ribose, low melting-point agarose, Lac, xylitol, Raffinose, glucose, malic acid, citric acid, isomalt, lactose, maltose etc., and they contain the water of crystallization chemical compound; Said plasticity substrate is selected from the natural adjuvant of following one or more plant origins: starch and derivant thereof, cellulose and derivant thereof, arabic gum, dextran, chitin, sesbania gum, carrageenan, Ficus elastica, Furcellaran, tragakanta, carrageenin, tamarind gum, pectin, xanthan gum, alginic acid and salt thereof, dextrin, cyclodextrin, agar, lactose; Described starch and derivant thereof such as pregelatinized Starch, modified starch, hydroxypropyl starch, carboxymethyl starch, described cellulose and derivant thereof such as methylcellulose, microcrystalline Cellulose, sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose, cross-linking sodium carboxymethyl cellulose, hydroxyethylmethyl-cellulose, hydroxyethyl-cellulose, hydroxypropyl cellulose.
Medicine preferred of the present invention is formed and is comprised: Borneolum Syntheticum 0.8～2 weight portion, Rhizoma Acori Graminei 25～35 weight portions, Rhizoma Chuanxiong 25～35 weight portions, the Radix Angelicae Dahuricae 25～35 weight portions, appropriate amount of auxiliary materials, filler adjuvant wherein is selected from following one or more the natural adjuvant of plant origin: sorbitol, xylitol, lactose, maltose, and they contain the water of crystallization chemical compound; Plasticity substrate wherein is selected from following one or more the natural adjuvant of plant origin: pregelatinized Starch, carboxymethyl starch, methylcellulose, sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose, arabic gum, alginic acid, dextrin, cyclodextrin, agar, lactose.
Best medicine of the present invention is formed and is comprised: Borneolum Syntheticum 1 weight portion, Rhizoma Acori Graminei 30 weight portions, Rhizoma Chuanxiong 30 weight portions, the Radix Angelicae Dahuricae 30 weight portions, appropriate amount of auxiliary materials are made, and filler adjuvant wherein is selected from following one or more the natural adjuvant of plant origin: xylitol, lactose; Plasticity substrate wherein is selected from following one or more the natural adjuvant of plant origin: starch, arabic gum.
Can also contain chemosynthesis adjuvant and animal origin adjuvant in the above-mentioned dressing, wherein filler comprises phenylglycol, hexadecanol, octadecanol, sodium stearate, tristerin, tripalmitin, carbamide, polyoxyethylene monostearate, polyoxyethylene alkyl ether; Wherein plasticity substrate comprises polyvinylpyrrolidone, crospolyvinylpyrrolidone, carbomer, polyvinyl alcohol, acrylic resin, poloxamer, gelatin.
At ratio of adjuvant molding is found in the sex research, in the combination of xylitol and starch, lactose and starch, xylitol and arabic gum, low melting point substrate adjuvant is 1: 0～1: 1.5 with the ratio of the weight of plasticity substrate adjuvant, be preferably 1: 0.1～1: 0.9, the best is 1: 0.1～1: 0.5.Specific to each combination, xylitol is 1: 0.2～1: 0.3 with the ratio of the weight of starch; Lactose is 1: 0.2～1: 0.3 with the ratio of the weight of starch; The ratio of the weight of xylitol and arabic gum is 1: 0.2～1: 0.4.
Medicine mesostroma adjuvant of the present invention and amount of drug are than can being the scope that allows on the galenic pharmacy, medicine described here can be that crude drug also can be the effective ingredient extract, in order to adapt to industrialized great production, the ratio range of mesostroma adjuvant of the present invention and medicine refers to the weight proportion of adjuvant and extract drugs effective ingredient, and the substrate adjuvant is 1: 0.1～1: 1 with the ratio of the weight of effective ingredient; Preferred substrate adjuvant is 1: 0.1～1: 0.6 with the ratio of the weight of effective ingredient; Best substrate adjuvant is 1: 0.2～1: 0.4 with the ratio of effective ingredient weight.
Medicine of the present invention can adopt the preparation of Chinese medicine preparation conventional method.The preparation of effective ingredient of the present invention can be adopted following method: water extraction, decoction and alcohol sedimentation technique, extraction, infusion process, percolation, reflux extraction, continuous backflow extraction method, macroreticular resin absorbing method preparation.For example, these crude drug pulverize mix homogeneously can be made powder takes after mixing it with water; Also can be with these medicines decocting together, the condensed water decocting liquid is made oral liquid then; But in order to make each crude drug of this medicine better bring into play drug effect, preferably adopt following technology to extract, make dropping pill formulation, but this can not limit protection scope of the present invention raw material.
The preparation method of medicine of the present invention is as follows:
(a): get Borneolum Syntheticum 0.5～3 weight portion, Rhizoma Acori Graminei 15～40 weight portions, Rhizoma Chuanxiong 15～40 weight portions, the Radix Angelicae Dahuricae 15～40 weight portions are standby;
(b): get Rhizoma Acori Graminei, Rhizoma Chuanxiong, Radix Angelicae Dahuricae decoction pieces and add the above water logging bubble of 5 times of amounts more than 1 hour, steam distillation separates, and it is standby to collect volatile oil; Separate the volatile oil after-filtration, get medicinal residues and filtrate I, other device of filtrate I is stored for future use; The medicinal residues that extract behind the volatile oil are added water more than 3 times, decoct once or more than, be no less than 1h at every turn, filtrate and the filtrate I that decocts several times merged, filter, get filtrate II; Filtrate II is concentrated, and drying is pulverized, and sieves, and it is standby to get dry powder; Borneolum Syntheticum is pulverized, and sieves, and adds in the above dry powder and stirs; The volatile oil of carrying is dissolved in an amount of ethanol, evenly is sprayed in the above dry powder, stir, get raw material medicated powder;
(c): in appropriate amount of auxiliary materials, add above-mentioned raw materials medicated powder, fully mix, mixture stirs at 45～115 ℃ of heating and meltings, and mixing time is 1～120 minute, insulation, at 45～95 ℃ of temperature following system, dropper bore is 1.0～4.0 millimeters, splashes in-20～25 ℃ liquid paraffin, methyl-silicone oil or the vegetable oil, with the drop pill drop that forms to the greatest extent and wipe liquid coolant, make drop pill, promptly.
Preferred manufacturing procedure comprises the following steps:
(a): get Borneolum Syntheticum 0.8～2 weight portion, Rhizoma Acori Graminei 25～35 weight portions, Rhizoma Chuanxiong 25～35 weight portions, the Radix Angelicae Dahuricae 25～35 weight portions are standby;
(b): get Rhizoma Acori Graminei, Rhizoma Chuanxiong, Radix Angelicae Dahuricae decoction pieces and add the above water logging bubble of 8 times of amounts 2～4 hours, steam distillation separates, and it is standby to collect volatile oil; Separate the volatile oil after-filtration, get medicinal residues and filtrate I, other device of filtrate I is stored for future use; Medicinal residues behind the extraction volatile oil are added 8～10 times in water, decoct 2～3 times, each 2h～4h merges filtrate and the filtrate I that decocts several times, filters, and gets filtrate II; Filtrate II is concentrated, and drying is pulverized, and sieves, and it is standby to get dry powder; Borneolum Syntheticum is pulverized, and sieves, and adds in the above dry powder and stirs; The volatile oil of carrying is dissolved in an amount of ethanol, evenly is sprayed in the above dry powder, stir, get raw material medicated powder;
(c): in appropriate amount of auxiliary materials, add above-mentioned raw materials medicated powder, fully mix, mixture stirs at 60～85 ℃ of heating and meltings, mixing time is 10～30 minutes, insulation is 1.1～3.5 millimeters at 60～85 ℃ of temperature following system, dropper bore, splashes in 0～18 ℃ the liquid paraffin, methyl-silicone oil, liquid coolant is use up and wiped to the drop pill drop that forms, back packing to be dried is made drop pill, promptly.
Best preparation method comprises the following steps:
(a): get Borneolum Syntheticum 1 weight portion, Rhizoma Acori Graminei 30 weight portions, Rhizoma Chuanxiong 30 weight portions, the Radix Angelicae Dahuricae 30 weight portions are standby;
(b): get Rhizoma Acori Graminei, Rhizoma Chuanxiong, Radix Angelicae Dahuricae decoction pieces and add the above water logging bubble of 8 times of amounts 2～4 hours, steam distillation separates, and it is standby to collect volatile oil; Separate the volatile oil after-filtration, get medicinal residues and filtrate I, other device of filtrate I is stored for future use; Medicinal residues behind the extraction volatile oil are added 8～10 times in water, decoct 2～3 times, each 2h～4h merges filtrate and the filtrate I that decocts several times, filters, and gets filtrate II; Filtrate II is concentrated, and drying is pulverized, and sieves, and it is standby to get dry powder; Borneolum Syntheticum is pulverized, and sieves, and adds in the above dry powder and stirs; The volatile oil of carrying is dissolved in an amount of ethanol, evenly is sprayed in the above dry powder, stir, get raw material medicated powder;
(c): in appropriate amount of auxiliary materials, add above-mentioned raw materials medicated powder, fully mix, mixture stirs at 64 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 64 ℃ of temperature following system, dropper bore is 1.2～2.5 millimeters, splashes in 0 ℃ the methyl-silicone oil, with the drop pill drop that forms to the greatest extent and wipe liquid coolant, back packing to be dried is made drop pill promptly.
The best preparation method of medicine of the present invention is:
(a): get Borneolum Syntheticum 1 weight portion, Rhizoma Acori Graminei 30 weight portions, Rhizoma Chuanxiong 30 weight portions, the Radix Angelicae Dahuricae 30 weight portions are standby;
(b): get Rhizoma Acori Graminei, Rhizoma Chuanxiong, Radix Angelicae Dahuricae decoction pieces and add the above water logging bubble of 8 times of amounts 2～4 hours, steam distillation separates, and it is standby to collect volatile oil; Separate the volatile oil after-filtration, get medicinal residues and filtrate I, other device of filtrate I is stored for future use; Medicinal residues behind the extraction volatile oil are added 8～10 times in water, decoct 2～3 times, each 2h～4h merges filtrate and the filtrate I that decocts several times, filters, and gets filtrate II; Filtrate II is concentrated, and drying is pulverized, and sieves, and it is standby to get dry powder; Borneolum Syntheticum is pulverized, and sieves, and adds in the above dry powder and stirs; The volatile oil of carrying is dissolved in an amount of ethanol, evenly is sprayed in the above dry powder, stir, get raw material medicated powder;
(c): to xylitol and starch, xylitol is 1: 0.2～1: 0.3 with the ratio of the weight of starch; Or be lactose and starch, lactose is 1: 0.2～1: 0.3 with the ratio of the weight of starch; Or be xylitol and arabic gum, the ratio of the weight of xylitol and arabic gum is to add above-mentioned Radix Angelicae Dahuricae extract and Rhizoma Chuanxiong extractum in 1: 0.2～1: 0.4 the mixture, fully mixes, and mixture is at 64 ℃ of heating and meltings, stir, mixing time is 10～30 minutes, and insulation is 1.2～2.5 millimeters at 64 ℃ of temperature following system, dropper bore and splashes in 0 ℃ the methyl-silicone oil, liquid coolant is use up and wiped to the drop pill drop that forms, back packing to be dried is made drop pill, promptly.
More than form when producing and to increase or to reduce according to corresponding ratio, as large-scale production can be unit with kilogram or with the ton, small-scale production can be unit with the gram also, and weight can increase or reduce, but the crude drug material weight proportion constant rate between each composition.
More than each single medicinal material, especially adjuvant drug, messenger drug or adjuvant drug and messenger drug in forming, can be replaced by suitable Chinese medicine individually or simultaneously with the identical property of medicine, effect, it is constant to replace back Chinese medicine preparation and drug effect thereof.
Medicine of the present invention can be determined usage and dosage according to patient's situation in use, but every day 1-3 time, and every day, each crude drug consumption was as the criterion with the state-promulgated pharmacopoeia dosage, was no more than the pharmacopeia ormal weight.
The drop pill that the present invention is prepared, conventional drop pill advantage is simple as preparing except having, steady quality, can make liquid medicine solidification, convenient drug administration, efficient, quick-acting, its biggest advantage is:
1, the selected adjuvant pure natural of the present invention degree height: the substrate adjuvant that employed substrate adjuvant derives from natural plants or originates based on natural plants among the present invention, for example: selected substrate adjuvant is xylitol and starch or lactose and starch or xylitol and arabic gum, this substrate adjuvant has pure natural degree height, toxic and side effects is low, mouthfeel is good, dissolve scattered time limit is short, rapid-action, it is a kind of new medium adjuvant, can be used for substituting present chemosynthesis substrate adjuvant, the drop pill made from this kind adjuvant, it is low to solve the pure natural degree that present drop pill substrate faced, and more and more can not satisfy people and require back to nature, take low toxicity, the problem of the pure natural medical that has no side effect.
2, some problems in the outlet of solution Chinese medicine: medicine of the present invention also can solve Chinese medicine preparation, some problems of in exit procedure, being run into of dropping pill formulation particularly, solve because different countries, especially the European countries of industry prosperity are to the difference identification of the selected adjuvant of Chinese medicine dropping pill formulation, overcome as the selected adjuvant Polyethylene Glycol of the dropping pill formulation of the health food outlet defective in some national food additive catalogue not, improve the Chinese medicine dripping pills preparation and move towards the international market, strengthen the competitiveness of international market.
3, solve the relatively poor problem of drop pill taste and further improve drug effect speed (dissolve scattered time limit): the medicinal dropping ball made from this kind substrate adjuvant of the present invention, can improve Chinese medicine preparation, the particularly present not good shortcoming of dropping pill formulation taste, improve mouthfeel, more easy for patients to accept, and the drop pill that adopts the selected adjuvant of medicine of the present invention to make has shorter dissolve scattered time limit, making drug effect faster, is the medicine that headache is treated in a kind of onset faster.
4, higher safety and solve some problems in the drop pill storage process: the selected substrate of the present invention is not only additive, nutrient commonly used in the food industry, and can do medicinal, but do not see that it uses as the drug matrices adjuvant, therefore, with regard to substrate, be perfectly safe, have no side effect, a large amount of evidences, the drop pill that this adjuvant is made can reduce effective ingredient separating out in storage process, the sticking ball of drop pill, easy shortcomings such as moisture absorption deliquescing, but the big production of suitability for industrialized.
The present invention is under instruction of Chinese Medicine theory, preparation technology's test that process is a large amount of and pharmacology, the resulting preparation of pharmacodynamics test.Reasonable recipe of the present invention, selected excipient substance pure natural property height, toxic and side effects are low, it is bigger to have overcome western medicine headache drug side effect, and the Chinese medicine curative effect is low, flavour of a drug are many, the shortcoming of decoction incompatibility large-scale production, is the medicine that treatment that a kind of economy, material benefit, curative effect are determined is had a headache.
The present invention is under instruction of Chinese Medicine theory, preparation technology's test that process is a large amount of and pharmacology, the resulting preparation of pharmacodynamics test.The present invention is through a large amount of preparation technology's test and pharmacology, the resulting preparation of pharmacodynamics test, has expelling wind and cold, the effect of promoting blood circulation to remove obstruction in the collateral.Be applicable to treatment headache wind and cold congestion retardance venation card, disease is seen distending pain in the head or twinge, localized pain, and outbreak is repeatedly met wind and cold and is brought out or disease such as increase the weight of.
To those skilled in the art, technology contents disclosed according to the present invention, those skilled in the art will very clear other embodiment of the present invention, and the embodiment of the invention is only as example.Under the situation of not violating purport of the present invention and scope, can carry out various changes and improvements to the present invention.For example, use different crude drug or extract or active constituents of medicine or effective ingredient and adjuvant provided by the present invention to make various different preparations, particularly drop pill, but as long as use adjuvant of the present invention, all within protection domain of the present invention.
In order to understand the present invention better, below with the new substrate drop pill of the present invention, according to embodiment 1 method preparation (providing), hereinafter to be referred as newly by the Jinshili Medicine Research ﹠. Development Co., Ltd., Tianjin; With the Polyethylene Glycol is the drop pill that adjuvant is made, (according to application number be: 200310117239.9 documents and materials embodiment one preparation), hereinafter to be referred as old, contrast tests such as the dissolve scattered time limit by observing the two, drop pill soft durometer, the sticking ball of drop pill illustrate advantage of the present invention.
Test example 1: dissolve scattered time limit, the different contrast experiment's example of the ball method of double differences
In vitro tests
The present invention be that the drop pill that adjuvant is made compares with the Polyethylene Glycol, by measuring index such as dissolve scattered time limit, investigate its good releasing effect; Whether by weight differential, it is ripe to investigate its preparation technology, whether is fit to suitability for industrialized production.
1. test medication: the new substrate drop pill of the present invention (newly); With the Polyethylene Glycol is the drop pill (old) that adjuvant is made.
2. method and result:
Dissolve scattered time limit: by " method is measured under this item of Chinese pharmacopoeia; The ball method of double differences is different: by " method is measured under this item of Chinese pharmacopoeia.Result of the test sees Table 1.
The new substrate drop pill of three crowdes of the present invention of table 1 (newly) with the polyethylene glycol 6000 be drop pill (old) dissolve scattered time limit made of adjuvant, weight differential relatively
Test data shows, the dissolve scattered time limit of new substrate drop pill is than being that the drop pill that adjuvant is made lacks with the Polyethylene Glycol; The ball weight differential of new substrate drop pill to be that the drop pill made of adjuvant is similar with the Polyethylene Glycol.Presentation of results, molten diffusing speed with the new substrate drop pill of the present invention is faster, is more conducive to medicine and plays a role in the shortest time, and the ball method of double differences of the new substrate drop pill of the present invention is different all to be controlled in the pharmacopeia prescribed limit, the alternative present chemosynthesis adjuvant of this natural substrates adjuvant is described, but suitability for industrialized production.
Test example 2: new substrate drop pill of the present invention and the sticking ball comparative observation of hardness, drop pill that with the polyethylene glycol 6000 is the drop pill made of adjuvant
According to literature method preparation is three batches of the drop pill of adjuvant with the Polyethylene Glycol, is loaded in the porcelain vase respectively, and uses the bottle stopper good seal.Putting it into the bottom has in the exsiccator of saturated Nacl (humidity 75%) solution, exsiccator is put into 40 ℃ of drying baker of constant temperature again, and timing sampling is observed situations such as drop pill soft durometer, the sticking ball of drop pill, the results are shown in Table 2.1, table 2.2.
Three batches in table 2.1 is that the drop pill reserved sample observing that adjuvant is made compares with the polyethylene glycol 6000
Table 2.2: three batches of drop pill made from the new medium adjuvant (newly) with the polyethylene glycol 6000 be drop pill (old) character observation made of adjuvant relatively
Above test data shows, the new substrate drop pill of the present invention be the drop pill soft durometer made of adjuvant with the Polyethylene Glycol, that drop pill glues the ball situation is similar, it is the drop pill that substrate is made that the new substrate drop pill of the present invention is better than slightly with the Polyethylene Glycol.Result of the test explanation, the sticking ball of soft durometer, drop pill of the new substrate drop pill made from novel adjuvant of the present invention does not have significant change, and the alternative present chemosynthesis adjuvant of this natural substrates adjuvant is described, but suitability for industrialized production.
The specific embodiment
Embodiment 1
(a): get Borneolum Syntheticum 1g, Rhizoma Acori Graminei 30g, Rhizoma Chuanxiong 30g, Radix Angelicae Dahuricae 30g, xylitol 18g, starch 4.5g are standby;
(b): get Rhizoma Acori Graminei, Rhizoma Chuanxiong, Radix Angelicae Dahuricae decoction pieces and add the above water logging bubble of 8 times of amounts 2～4 hours, steam distillation separates, and it is standby to collect volatile oil; Separate the volatile oil after-filtration, get medicinal residues and filtrate I, other device of filtrate I is stored for future use; Medicinal residues behind the extraction volatile oil are added 8～10 times in water, decoct 2～3 times, each 2h～4h merges filtrate and the filtrate I that decocts several times, filters, and gets filtrate II; Filtrate II is concentrated, and drying is pulverized, and sieves, and it is standby to get dry powder; Borneolum Syntheticum is pulverized, and sieves, and adds in the above dry powder and stirs; The volatile oil of carrying is dissolved in an amount of ethanol, evenly is sprayed in the above dry powder, stir, get raw material medicated powder;
(c): xylitol and starch are fully mixed, add above-mentioned raw materials medicated powder, mixture stirs at 60～85 ℃ of heating and meltings, and mixing time is 5～30 minutes, insulation, at 60～70 ℃ of temperature following system, dropper bore is 1.0～4.0 millimeters, splashes in 5～15 ℃ the liquid paraffin, with the drop pill drop that forms to the greatest extent and wipe liquid coolant, make 1000 drop pill, promptly.
Embodiment 2
(a): get Borneolum Syntheticum 0.8g, Rhizoma Acori Graminei 25g, Rhizoma Chuanxiong 25g, Radix Angelicae Dahuricae 35g, lactose 17.3g, starch 5.2g are standby;
(b): get the water logging bubble 4 hours that Rhizoma Acori Graminei, Rhizoma Chuanxiong, Radix Angelicae Dahuricae decoction pieces add 10 times of amounts, steam distillation separates, and it is standby to collect volatile oil; Separate the volatile oil after-filtration, get medicinal residues and filtrate I, other device of filtrate I is stored for future use; Medicinal residues behind the extraction volatile oil are added 8 times in water, decoct 3 times, each 2h merges filtrate and the filtrate I that decocts several times, filters, and gets filtrate II; Filtrate II is concentrated, and drying is pulverized, and sieves, and it is standby to get dry powder; Borneolum Syntheticum is pulverized, and sieves, and adds in the above dry powder and stirs; The volatile oil of carrying is dissolved in an amount of ethanol, evenly is sprayed in the above dry powder, stir, get raw material medicated powder;
(c): with mixing of lactose and starch, place in the container, add above-mentioned raw materials medicated powder, fully mix, mixture stirs at 60～85 ℃ of heating and meltings, mixing time is 10～30 minutes, insulation is 1.1～3.5 millimeters at 60～85 ℃ of temperature following system, dropper bore, splashes in 0～18 ℃ the methyl-silicone oil, liquid coolant is use up and wiped to the drop pill drop that forms, back packing to be dried is made 1000 drop pill, promptly.
Embodiment 3
(a): get Borneolum Syntheticum 2g, Rhizoma Acori Graminei 35g, Rhizoma Chuanxiong 35g, Radix Angelicae Dahuricae 35g, xylitol 18.75g, arabic gum 3.25g are standby;
(b): get Rhizoma Acori Graminei, Rhizoma Chuanxiong, Radix Angelicae Dahuricae decoction pieces and add the above water logging bubble of 12 times of amounts 4 hours, steam distillation separates, and it is standby to collect volatile oil; Separate the volatile oil after-filtration, get medicinal residues and filtrate I, other device of filtrate I is stored for future use; Medicinal residues behind the extraction volatile oil are added 10 times in water, decoct 2 times, each 4h merges filtrate and the filtrate I that decocts several times, filters, and gets filtrate II; Filtrate II is concentrated, and drying is pulverized, and sieves, and it is standby to get dry powder; Borneolum Syntheticum is pulverized, and sieves, and adds in the above dry powder and stirs; The volatile oil of carrying is dissolved in an amount of ethanol, evenly is sprayed in the above dry powder, stir, get raw material medicated powder;
(c): with the mixing of xylitol and arabic gum, place in the container, add above-mentioned raw materials medicated powder, fully mix, mixture stirs at 60～85 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 60～85 ℃ of temperature following system, dropper bore is 1.2～2.5 millimeters, and liquid coolant is use up and wiped to the liquid paraffin that splashes into 0～18 ℃ with the drop pill drop that forms, back packing to be dried, make 1000 drop pill, promptly.
Embodiment 4
(a): get Borneolum Syntheticum 1.2g, Rhizoma Acori Graminei 28g, Rhizoma Chuanxiong 28g, Radix Angelicae Dahuricae 31.5g, xylitol 22.5g, starch 16.85g are standby;
(b): get Rhizoma Acori Graminei, Rhizoma Chuanxiong, Radix Angelicae Dahuricae decoction pieces and add the above water logging bubble of 8 times of amounts 2～4 hours, steam distillation separates, and it is standby to collect volatile oil; Separate the volatile oil after-filtration, get medicinal residues and filtrate I, other device of filtrate I is stored for future use; Medicinal residues behind the extraction volatile oil are added 8～10 times in water, decoct 2～3 times, each 2h～4h merges filtrate and the filtrate I that decocts several times, filters, and gets filtrate II; Filtrate II is concentrated, and drying is pulverized, and sieves, and it is standby to get dry powder; Borneolum Syntheticum is pulverized, and sieves, and adds in the above dry powder and stirs; The volatile oil of carrying is dissolved in an amount of ethanol, evenly is sprayed in the above dry powder, stir, get raw material medicated powder;
(c): xylitol, starch are mixed evenly, add above-mentioned raw materials medicated powder, make granule, tabletting is made 1000, promptly.
Embodiment 5
(a): get Borneolum Syntheticum 3g, Rhizoma Acori Graminei 40g, Rhizoma Chuanxiong 40g, Radix Angelicae Dahuricae 40g, xylitol 18.5g, starch 9.0g are standby;
(b): get the water logging bubble 5 hours that Rhizoma Acori Graminei, Rhizoma Chuanxiong, Radix Angelicae Dahuricae decoction pieces add 6 times of amounts, steam distillation separates, and it is standby to collect volatile oil; Separate the volatile oil after-filtration, get medicinal residues and filtrate I, other device of filtrate I is stored for future use; Medicinal residues behind the extraction volatile oil are added 9 times in water, decoct 4 times, each 3h merges filtrate and the filtrate I that decocts several times, filters, and gets filtrate II; Filtrate II is concentrated, and drying is pulverized, and sieves, and it is standby to get dry powder; Borneolum Syntheticum is pulverized, and sieves, and adds in the above dry powder and stirs; The volatile oil of carrying is dissolved in an amount of ethanol, evenly is sprayed in the above dry powder, stir, get raw material medicated powder;
(c): xylitol and starch are mixed, place in the container, add above-mentioned raw materials medicated powder, fully mix, make capsule, promptly.
Embodiment 6
(a): get Borneolum Syntheticum 0.5g, Rhizoma Acori Graminei 15g, Rhizoma Chuanxiong 15g, Radix Angelicae Dahuricae 15g, xylitol 25.6g, pectin 9.4g are standby;
(b): get the water logging bubble 12 hours that Rhizoma Acori Graminei, Rhizoma Chuanxiong, Radix Angelicae Dahuricae decoction pieces add 7 times of amounts, steam distillation separates, and it is standby to collect volatile oil; Separate the volatile oil after-filtration, get medicinal residues and filtrate I, other device of filtrate I is stored for future use; Medicinal residues behind the extraction volatile oil are added 9 times in water, decoct 3 times, the 1st 3h, the 2nd 2h, the 3rd 1h with the filtrate and the filtrate I merging of 3 decoctions, filters, and gets filtrate II; Filtrate II is concentrated, and drying is pulverized, and sieves, and it is standby to get dry powder; Borneolum Syntheticum is pulverized, and sieves, and adds in the above dry powder and stirs; The volatile oil of carrying is dissolved in an amount of ethanol, evenly is sprayed in the above dry powder, stir, get raw material medicated powder;
(c): xylitol, pectin are mixed evenly, place in the container, add above-mentioned raw materials medicated powder, fully mix, mixture stirs at 64 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 64 ℃ of temperature following system, dropper bore is 1.2～2.5 millimeters, splashes in 0 ℃ the methyl-silicone oil, with the drop pill drop that forms to the greatest extent and wipe liquid coolant, back packing to be dried is made 1000 drop pill promptly.
Embodiment 7
(a): get Borneolum Syntheticum 2g, Rhizoma Acori Graminei 30g, Rhizoma Chuanxiong 40g, Radix Angelicae Dahuricae 35g, xylitol 20.5g, chitin 6.2g, xanthan gum 4.3g are standby;
(b): get the water logging bubble 10 hours that Rhizoma Acori Graminei, Rhizoma Chuanxiong, Radix Angelicae Dahuricae decoction pieces add 12 times of amounts, steam distillation separates, and it is standby to collect volatile oil; Separate the volatile oil after-filtration, get medicinal residues and filtrate I, other device of filtrate I is stored for future use; Medicinal residues behind the extraction volatile oil are added 12 times in water, decoct 2 times, each 2h with the filtrate and the filtrate I merging of twice decoction, filters, and gets filtrate II; Filtrate II is concentrated, and drying is pulverized, and sieves, and it is standby to get dry powder; Borneolum Syntheticum is pulverized, and sieves, and adds in the above dry powder and stirs; The volatile oil of carrying is dissolved in an amount of ethanol, evenly is sprayed in the above dry powder, stir, get raw material medicated powder;
(c): xylitol, chitin, xanthan gum are mixed evenly, place in the container, add above-mentioned raw materials medicated powder, fully mix, mixture stirs at 64 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 64 ℃ of temperature following system, dropper bore is 1.2～2.5 millimeters, splashes in 0 ℃ the methyl-silicone oil, with the drop pill drop that forms to the greatest extent and wipe liquid coolant, back packing to be dried is made 1000 drop pill promptly.
Embodiment 8
(a): get Borneolum Syntheticum 1.5g, Rhizoma Acori Graminei 31.5g, Rhizoma Chuanxiong 25g, Radix Angelicae Dahuricae 40g, Furcellaran 5g, sorbitol 15g, carboxymethyl starch 3.5g are standby;
(b): get Rhizoma Acori Graminei, Rhizoma Chuanxiong, Radix Angelicae Dahuricae decoction pieces and add the above water logging bubble of 5 times of amounts more than 1 hour, steam distillation separates, and it is standby to collect volatile oil; Separate the volatile oil after-filtration, get medicinal residues and filtrate I, other device of filtrate I is stored for future use; The medicinal residues that extract behind the volatile oil are added water more than 3 times, decoct once or more than, be no less than 1h at every turn, filtrate and the filtrate I that decocts several times merged, filter, get filtrate II; Filtrate II is concentrated, and drying is pulverized, and sieves, and it is standby to get dry powder; Borneolum Syntheticum is pulverized, and sieves, and adds in the above dry powder and stirs; The volatile oil of carrying is dissolved in an amount of ethanol, evenly is sprayed in the above dry powder, stir, get raw material medicated powder;
(c): Furcellaran, sorbitol, carboxymethyl starch are mixed evenly, place in the container, add above-mentioned raw materials medicated powder, fully mix, mixture stirs at 58～64 ℃ of heating and meltings, and mixing time is 30～50 minutes, insulation, at 58～64 ℃ of temperature following system, dropper bore is 1.25～2.5 millimeters, splashes in 10 ℃ the methyl-silicone oil, with the drop pill drop that forms to the greatest extent and wipe liquid coolant, back packing to be dried is made 1000 drop pill promptly.
Embodiment 9
(a): get raw material medicated powder 8.5g, the xylitol 20.4g, starch 4.1g, the tragakanta 2g that obtain according to embodiment 1 method;
(b): xylitol, starch, tragakanta are mixed evenly, place in the container, add above-mentioned Radix Angelicae Dahuricae extract and Rhizoma Chuanxiong extractum, fully mix, mixture stirs at 64 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 64 ℃ of temperature following system, dropper bore is 1.2～2.5 millimeters, splashes in 0 ℃ the methyl-silicone oil, with the drop pill drop that forms to the greatest extent and wipe liquid coolant, back packing to be dried is made 1000 drop pill promptly.
Embodiment 10
(a): get Borneolum Syntheticum 0.5g, Rhizoma Acori Graminei 20g, Rhizoma Chuanxiong 20g, Radix Angelicae Dahuricae 35g, xylitol 13.5g, starch 9g are standby;
(b): get Rhizoma Acori Graminei, Rhizoma Chuanxiong, Radix Angelicae Dahuricae decoction pieces and add the above water logging bubble of 8 times of amounts 2～4 hours, steam distillation separates, and it is standby to collect volatile oil; Separate the volatile oil after-filtration, get medicinal residues and filtrate I, other device of filtrate I is stored for future use; Medicinal residues behind the extraction volatile oil are added 8～10 times in water, decoct 2 times, each 4h merges filtrate and the filtrate I that decocts several times, filters, and gets filtrate II; Filtrate II is concentrated, and drying is pulverized, and sieves, and it is standby to get dry powder; Borneolum Syntheticum is pulverized, and sieves, and adds in the above dry powder and stirs; The volatile oil of carrying is dissolved in an amount of ethanol, evenly is sprayed in the above dry powder, stir, get raw material medicated powder;
(c): in xylitol and starch mixture, add above-mentioned raw materials medicated powder, fully mix, mixture stirs at 64 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 64 ℃ of temperature following system, dropper bore is 1.2～2.5 millimeters, splashes in 0 ℃ the methyl-silicone oil, with the drop pill drop that forms to the greatest extent and wipe liquid coolant, back packing to be dried is made 1000 drop pill promptly.
Embodiment 11
(a): get Borneolum Syntheticum 1.5g, Rhizoma Acori Graminei 18g, Rhizoma Chuanxiong 35g, Radix Angelicae Dahuricae 35g, lactose 13.5g, starch 9g are standby;
(b): get Rhizoma Acori Graminei, Rhizoma Chuanxiong, Radix Angelicae Dahuricae decoction pieces and add the above water logging bubble of 8 times of amounts 2～4 hours, steam distillation separates, and it is standby to collect volatile oil; Separate the volatile oil after-filtration, get medicinal residues and filtrate I, other device of filtrate I is stored for future use; Medicinal residues behind the extraction volatile oil are added 15 times in water, decoct 3 times, each 2h merges filtrate and the filtrate I that decocts several times, filters, and gets filtrate II; Filtrate II is concentrated, and drying is pulverized, and sieves, and it is standby to get dry powder; Borneolum Syntheticum is pulverized, and sieves, and adds in the above dry powder and stirs; The volatile oil of carrying is dissolved in an amount of ethanol, evenly is sprayed in the above dry powder, stir, get raw material medicated powder;
(c): in lactose and starch mixture, add above-mentioned raw materials medicated powder, fully mix, mixture stirs at 64 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 64 ℃ of temperature following system, dropper bore is 1.2～2.5 millimeters, splashes in 0 ℃ the methyl-silicone oil, with the drop pill drop that forms to the greatest extent and wipe liquid coolant, back packing to be dried is made 1000 drop pill promptly.
Embodiment 12
(a): get Borneolum Syntheticum 0.6g, Rhizoma Acori Graminei 25g, Rhizoma Chuanxiong 25g, Radix Angelicae Dahuricae 25g, xylitol 13.5g, arabic gum 9g are standby;
(b): get the water logging bubble 4 hours that Rhizoma Acori Graminei, Rhizoma Chuanxiong, Radix Angelicae Dahuricae decoction pieces add 10 times of amounts, steam distillation separates, and it is standby to collect volatile oil; Separate the volatile oil after-filtration, get medicinal residues and filtrate I, other device of filtrate I is stored for future use; Medicinal residues behind the extraction volatile oil are added 10 times in water, decoct 4 times, each 3h merges filtrate and the filtrate I that decocts several times, filters, and gets filtrate II; Filtrate II is concentrated, and drying is pulverized, and sieves, and it is standby to get dry powder; Borneolum Syntheticum is pulverized, and sieves, and adds in the above dry powder and stirs; The volatile oil of carrying is dissolved in an amount of ethanol, evenly is sprayed in the above dry powder, stir, get raw material medicated powder;
(c): in xylitol and arabic gum mixture, add above-mentioned raw materials medicated powder, fully mix, mixture stirs at 64 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 64 ℃ of temperature following system, dropper bore is 1.2～2.5 millimeters, splashes in 0～15 ℃ the liquid paraffin, with the drop pill drop that forms to the greatest extent and wipe liquid coolant, back packing to be dried is made 1000 drop pill promptly.
Claims (4)
1. medicine for the treatment of headache, it is characterized in that this medicine composition comprises: Borneolum Syntheticum 1 weight portion, Rhizoma Acori Graminei 30 weight portions, Rhizoma Chuanxiong 30 weight portions, the Radix Angelicae Dahuricae 30 weight portions, appropriate amount of auxiliary materials, wherein adjuvant is xylitol and starch, and described xylitol is 1: 0.2～1: 0.3 with the ratio of the weight of starch; Adjuvant is 1: 0.1～1: 1 with the ratio of the weight of effective ingredient;
The preparation method of medicine comprises the following steps:
(a): get Borneolum Syntheticum 1 weight portion, Rhizoma Acori Graminei 30 weight portions, Rhizoma Chuanxiong 30 weight portions, the Radix Angelicae Dahuricae 30 weight portions are standby;
(b): get Rhizoma Acori Graminei, Rhizoma Chuanxiong, Radix Angelicae Dahuricae decoction pieces and add the above water logging bubble of 8 times of amounts 2～4 hours, steam distillation separates, and it is standby to collect volatile oil; Separate the volatile oil after-filtration, get medicinal residues and filtrate I, other device of filtrate I is stored for future use; Medicinal residues behind the extraction volatile oil are added 8～10 times in water, decoct 2～3 times, each 2h～4h merges filtrate and the filtrate I that decocts several times, filters, and gets filtrate II; Filtrate II is concentrated, and drying is pulverized, and sieves, and it is standby to get dry powder; Borneolum Syntheticum is pulverized, and sieves, and adds in the above dry powder and stirs; The volatile oil of carrying is dissolved in an amount of ethanol, evenly is sprayed in the above dry powder, stir, get raw material medicated powder;
(c): in appropriate amount of auxiliary materials, add above-mentioned raw materials medicated powder, fully mix, mixture stirs at 64 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 64 ℃ of temperature following system, dropper bore is 1.2～2.5 millimeters, splashes in 0 ℃ the methyl-silicone oil, with the drop pill drop that forms to the greatest extent and wipe liquid coolant, back packing to be dried is made drop pill promptly.
2. the medicine of treatment headache as claimed in claim 1 is characterized in that the adjuvant and the ratio of the weight of effective ingredient are 1: 0.1～1: 0.6.
3. the medicine of treatment headache as claimed in claim 2 is characterized in that the adjuvant and the ratio of the weight of effective ingredient are 1: 0.2～1: 0.4.
4. as any one described a kind of preparation method for the treatment of the medicine of headache in the claim 1 to 3, comprise the following steps:
(a): get Borneolum Syntheticum 1 weight portion, Rhizoma Acori Graminei 30 weight portions, Rhizoma Chuanxiong 30 weight portions, the Radix Angelicae Dahuricae 30 weight portions are standby;
(b): get Rhizoma Acori Graminei, Rhizoma Chuanxiong, Radix Angelicae Dahuricae decoction pieces and add the above water logging bubble of 8 times of amounts 2～4 hours, steam distillation separates, and it is standby to collect volatile oil; Separate the volatile oil after-filtration, get medicinal residues and filtrate I, other device of filtrate I is stored for future use; Medicinal residues behind the extraction volatile oil are added 8～10 times in water, decoct 2～3 times, each 2h～4h merges filtrate and the filtrate I that decocts several times, filters, and gets filtrate II; Filtrate II is concentrated, and drying is pulverized, and sieves, and it is standby to get dry powder; Borneolum Syntheticum is pulverized, and sieves, and adds in the above dry powder and stirs; The volatile oil of carrying is dissolved in an amount of ethanol, evenly is sprayed in the above dry powder, stir, get raw material medicated powder;
(c): in appropriate amount of auxiliary materials, add above-mentioned raw materials medicated powder, fully mix, mixture stirs at 64 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 64 ℃ of temperature following system, dropper bore is 1.2～2.5 millimeters, splashes in 0 ℃ the methyl-silicone oil, with the drop pill drop that forms to the greatest extent and wipe liquid coolant, back packing to be dried is made drop pill promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2005100136267A CN1872250B (en) | 2005-06-01 | 2005-06-01 | Composition of medication for treating headache |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2005100136267A CN1872250B (en) | 2005-06-01 | 2005-06-01 | Composition of medication for treating headache |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1872250A CN1872250A (en) | 2006-12-06 |
| CN1872250B true CN1872250B (en) | 2010-09-29 |
Family
ID=37482959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2005100136267A Expired - Fee Related CN1872250B (en) | 2005-06-01 | 2005-06-01 | Composition of medication for treating headache |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1872250B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107625796B (en) * | 2017-10-16 | 2021-07-06 | 中国人民解放军军事医学科学院毒物药物研究所 | Pharmaceutical composition containing radix angelicae and application thereof |
| CN108186825A (en) * | 2018-03-07 | 2018-06-22 | 黄振忠 | A kind of drug for treating gout |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1546136A (en) * | 2003-12-09 | 2004-11-17 | 北京正大绿洲医药科技有限公司 | Baras camphor, chuanxiong rhizome headache treating medicine and its oral preparation and its preparing process |
-
2005
- 2005-06-01 CN CN2005100136267A patent/CN1872250B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1546136A (en) * | 2003-12-09 | 2004-11-17 | 北京正大绿洲医药科技有限公司 | Baras camphor, chuanxiong rhizome headache treating medicine and its oral preparation and its preparing process |
Non-Patent Citations (1)
| Title |
|---|
| 王巍.第二军医大学硕士学位论文新基质复方丹参滴丸的研究.2004,全文. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1872250A (en) | 2006-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100553615C (en) | A kind of medicine for the treatment of cardiovascular and cerebrovascular disease | |
| CN1872250B (en) | Composition of medication for treating headache | |
| CN1872232B (en) | Composition of medication for curing cerebrovascular disease, and preparation method | |
| CN1872099B (en) | Medication for treating cardiovascular diseases, and cerebrovascular disease | |
| CN1872327B (en) | Composition of medicine for treating diarrhea | |
| CN100450504C (en) | Medication for treating pharyngitis | |
| CN1872230B (en) | A medication for treating coronary heart disease and preparation method | |
| CN100563673C (en) | Chinese medicine preparation of treatment angina pectoris and preparation method thereof | |
| CN1872216B (en) | Medication composition for treating headache, and preparation method | |
| CN100502840C (en) | Medication for treating chronic rhinitis and nasal sinusitis | |
| CN1872285B (en) | Drop pills of Chinese traditional medicine, and preparation method | |
| CN100563634C (en) | A kind of Herba Sidae Rhombifoliae soup drop pill | |
| CN100542517C (en) | Calculus bovis detoxifying dropping pill and preparation method thereof | |
| CN100421684C (en) | Medication for treating coronary heart disease and angina | |
| CN100512824C (en) | Medication for treating headache | |
| CN1872075B (en) | Drop pills of hemsleyadin, and preparation method | |
| CN1872111B (en) | Medication for treating cardiovascular diseases and cerebrovascular disease | |
| CN1872050B (en) | Drop pills of silymarin, and preparation method | |
| CN1872079B (en) | Drop pills for treating cardiovascular diseases and cerebrovascular disease, and preparation method | |
| CN100512832C (en) | Medication for treating ache | |
| CN100553620C (en) | A kind of medicine for the treatment of the thoracic obstruction | |
| CN1872139B (en) | Drop pills for treating bronchitis | |
| CN1872161B (en) | Drop pills of Chaihuang, and preparation method | |
| CN1872259B (en) | Composition of medicine for treating coronary heart disease | |
| CN1872036B (en) | Drop pills of agrimophol, and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARM. CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100929 Termination date: 20190601 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |